CORT: Revenue grew 64% YoY as Lifyorli uptake accelerated and guidance was reaffirmed

What happened

Corcept Therapeutics reported third-quarter revenue of $340.5 million, up 64% from a year earlier, including $91.4 million from Lifyorli. The company reaffirmed revenue guidance of $1.1 billion to $1.2 billion for the fiscal year. Management cited wider hypercortisolism screening, oncology growth, and upcoming clinical catalysts.

Confirmed

Global impact / market context

The reported growth and Lifyorli sales show that the drug contributed to current revenue, while reaffirmed guidance signals management still expects substantial revenue ahead. Wider screening could bring more patients into diagnosis and treatment, and oncology growth could add another source of sales, though neither outcome is quantified here.

Analyst inference

For investors, the key link is whether Lifyorli uptake and broader screening translate into sustained sales that support the stated annual revenue range. Oncology growth and clinical catalysts could widen future opportunities, but the supplied information gives no details on catalyst timing, results, costs, or expected sales.

Analyst inference

What to watch

1. Track whether later quarterly reports show Lifyorli revenue rising from $91.4 million and whether total revenue remains consistent with management’s reaffirmed revenue guidance. Analyst inference
2. Look for updates on broader hypercortisolism screening, including whether management reports measurable changes in diagnosis or treatment that could expand Lifyorli use. Analyst inference
3. Watch for details on the clinical catalysts management cited, including timing and results, because those developments could shape future treatment opportunities and sales expectations. Analyst inference

Evidence

• Original source link unavailable